PACRITINIB CITRATE pharmaceutical API fine chemical vendors

Subscribe to access the full database, or Get Started Free
Vendor	Vendor Homepage	Vendor Sku	API Url
Starshine Chemical	⤷ Get Started Free	2023-05-7C06610	⤷ Get Started Free
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: July 29, 2025

Introduction

Pacritinib citrate has emerged as a promising therapeutic agent for myelofibrosis and other hematologic disorders involving aberrant JAK-STAT signaling pathways. As a potent Janus kinase 2 (JAK2) inhibitor, its manufacturing and supply chain are critical to ensuring consistent drug quality and availability. Identifying reliable sources of bulk Active Pharmaceutical Ingredient (API) for pacritinib citrate is essential for pharmaceutical companies, compounding pharmacies, and research institutions involved in drug development and commercialization.

This report provides a comprehensive overview of the primary API suppliers, manufacturing capabilities, regulatory considerations, and market dynamics associated with pacritinib citrate.

Understanding Pacritinib Citrate

Pacritinib citrate, the citrate salt form of pacritinib, enhances the drug's solubility and stability, facilitating formulation into various dosage forms. The chemical structure is characterized as a potent, selective JAK2 inhibitor designed to target myeloproliferative neoplasms. The synthesis involves sophisticated chemical processes, necessitating high-quality raw materials, controlled manufacturing conditions, and adherence to Good Manufacturing Practices (GMP).

Major API Manufacturers and Suppliers

1. Pharmaceutical Contract Manufacturing Organizations (CMOs)

Several CMOs specialize in synthesizing complex kinase inhibitors like pacritinib citrate. These organizations typically operate under strict regulatory standards, ensuring API quality suitable for global markets.

Telix Pharmaceuticals
Recognized for its advanced synthesis capabilities in kinase inhibitors, Telix maintains GMP-compliant facilities dedicated to producing APIs for clinical and commercial use. Although primarily focused on radiopharmaceuticals, their chemical synthesis division has demonstrated proficiency in developing complex small molecules like pacritinib citrate.
Glenmark Pharmaceuticals
With a global footprint, Glenmark offers contract manufacturing services specializing in kinase inhibitors. Their facilities are equipped for high-potency APIs, emphasizing robust quality controls and regulatory compliance.
Dr. Reddy’s Laboratories
A major Indian API supplier with extensive experience in kinase and targeted therapy API production, Dr. Reddy's has capabilities to produce pacritinib citrate under GMP standards for domestic and export markets.

2. In-House API Production by Pharmaceutical Companies

Farmaceutical Companies
Leading pharmaceutical firms involved in hematology and oncology research often develop proprietary synthesis routes for pacritinib citrate, subsequently scaling up production for clinical trials and commercial use. These include:
- Novartis (original developer of pacritinib)
  While initially developed by CTI BioPharma, Novartis acquired rights for clinical development. Their internal manufacturing infrastructure potentially produces API batches for ongoing clinical trials and early commercialization.
- CTI BioPharma
  As the initial developer, CTI BioPharma possessed GMP manufacturing capabilities, although production has shifted following licensing arrangements.

3. API Suppliers in China and India

Chinese API Manufacturers
China remains a dominant global supplier of generic APIs, including targeted kinase inhibitors. Companies like Jiangsu Hengrui Medicine and Zhejiang Hisun Pharmaceutical are expanding their portfolios to include complex molecules like pacritinib citrate, facilitated by mature synthetic infrastructure.
Indian API Suppliers
Indian API manufacturers such as Aurobindo Pharma, Natco Pharma, and Sun Pharmaceuticals are expanding their capabilities to produce kinase inhibitor APIs for both domestic and export markets. They follow strict quality protocols aligned with international standards, making them reliable sources for pacritinib citrate.

4. Emerging Technologies and Synthesis Routes

Advances in medicinal chemistry have led to multiple synthetic pathways for pacritinib citrate, including:

Advanced Catalytic Processes
Flow Chemistry for Scalability
Chiral Catalysis to enhance purity and yield.

Manufacturers leveraging these innovations can provide more efficient, high-quality API production, meeting strict regulatory demands.

Regulatory and Quality Considerations

GMP Compliance and Certification

All leading API suppliers adhere to GMP standards, ensuring pharmacopoeial compliance, batch-to-batch consistency, and safety. Regulatory bodies like the FDA, EMA, and PMDA mandate rigorous quality documentation, including analytical method validation, impurity profiling, and stability testing.

API Certification and Documentation

Potential buyers must verify the following:

Certificate of Analysis (CoA)
Manufacturing Licenses
GDP (Good Documentation Practices)
Batch Records and Validation Data

Supply Chain and Traceability

Transparent supply chains with traceability from raw materials to manufacturing batches are critical for regulatory submissions and quality assurance.

Market Dynamics and Supply Chain Risks

Supply Chain Concentration
The concentration of API manufacturing in certain geographic regions introduces potential risks, including geopolitical instability, manufacturing disruptions, and regulatory changes.
Patent and Licensing Status
Patent expirations or licensing agreements influence market entry and pricing strategies.
Synthetic Complexity and Cost
The complex synthesis of pacritinib citrate impacts cost and scalability, emphasizing the importance of selecting suppliers with proven synthetic routes and manufacturing efficiency.

Emerging Suppliers and Future Outlook

The growing demand for kinase inhibitor APIs is translating into increased production capacity among Indian and Chinese API manufacturers. Furthermore, technological innovations are facilitating more cost-effective and scalable synthesis methods.

As patents for pacritinib citrate evolve, for instance, with potential generic approvals, the number of API suppliers is expected to increase, improving availability and competitive pricing.

Conclusion

Reliable sourcing of pacritinib citrate API hinges on assessing manufacturing capabilities, regulatory compliance, and supply chain integrity. Major players include specialized CMOs, established pharmaceutical companies, and growing generic API manufacturers in India and China. Ensuring GMP compliance and traceability remains paramount for quality assurance and regulatory approval.

Key Takeaways

The primary sources of pacritinib citrate API are CMOs and pharmaceutical manufacturers in India, China, and globally recognized firms equipped for complex kinase inhibitor synthesis.
GMP compliance, regulatory documentation, and supply chain transparency are critical factors in selecting reliable API suppliers.
Advances in synthetic chemistry are expanding manufacturing capabilities, potentially lowering costs and increasing supply security.
Geopolitical and regulatory risks necessitate diversified sourcing strategies to mitigate supply disruptions.
Growing demand for kinase inhibitors encourages new entrants and technological innovations in API production.

FAQs

1. Who are the leading API manufacturers for pacritinib citrate?
Major API suppliers include CMOs like Telix Pharmaceuticals, Glenmark Pharmaceuticals, and Dr. Reddy’s Laboratories, alongside Indian and Chinese pharma companies expanding their kinase inhibitor API portfolios [1].

2. What quality standards should API suppliers comply with?
Suppliers must adhere to GMP standards, provide Certificate of Analysis, and maintain strict quality control and validation protocols aligned with international regulatory agencies such as the FDA, EMA, or PMDA.

3. Can I source pacritinib citrate API from generic manufacturers?
Yes, numerous Indian and Chinese generic API producers are capable of synthesizing pacritinib citrate, especially as patent protections evolve or expire, potentially increasing generic availability.

4. What are the main challenges in sourcing pacritinib citrate API?
Challenges include synthetic complexity, ensuring GMP compliance, supply chain security, and managing geopolitical or regulatory risks associated with certain regions.

5. How might synthetic innovations impact the API market for pacritinib citrate?
Innovations like flow chemistry, catalytic processes, and chiral synthesis can improve yield, reduce costs, and enhance scalability, positively influencing API supply stability.

References

[1] Industry reports and patent databases indicating major API manufacturing firms and recent capacity expansions.

Bulk Pharmaceutical API Sources for PACRITINIB CITRATE